Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
Public ClinicalTrials.gov record NCT06087263. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT06087263
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 3 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 17, 2024
- Primary completion
- Jun 30, 2032
- Completion
- Jun 30, 2034
- Last update posted
- Jan 19, 2026
2024 – 2034
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Gastrointestinal Stromal Tumors trials
Other public records listing Gastrointestinal Stromal Tumors. Sorted by last update posted; newest first. Not a recommendation.
- NCT02012699: Integrated Cancer Repository for Cancer Research Recruiting
- NCT07171203: Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor Recruiting
- NCT05493215: Imatinib TDM in GIST Recruiting
- NCT03673501: A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib Active, not recruiting
- NCT06208748: SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST Active, not recruiting
- NCT06805825: A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06087263, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06087263 live on ClinicalTrials.gov.